List of Lumigan drug patents
Lumigan is owned by Allergan.
Lumigan contains Bimatoprost.
Lumigan has a total of 12 drug patents out of which 0 drug patents have expired.
Lumigan was authorised for market use on 31 August, 2010.
Lumigan is available in solution/drops;ophthalmic dosage forms.
Lumigan can be used as a method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient, a method of lowering intraocular pressure, method of treating glaucoma or elevated intraocular pressure, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension, a method of treating a patient with glaucoma or ocular hypertension, a method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The generics of Lumigan are possible to be released after 13 June, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7851504 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8278353 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8586630 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8524777 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US9155716 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8338479 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8772338 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8299118 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US9241918 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8309605 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8933120 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
| US8933127 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(1 year, 9 months from now) | |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 31 August, 2010
Treatment: A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A me...
Dosage: SOLUTION/DROPS;OPHTHALMIC
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic